Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 22 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 22 Jan 2018 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 01 Aug 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.